Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant strides in recent years, positioning itself as a frontrunner in the industry.

Sarasota Memorial Hospital has earned the #1 spot among the world's WATCHMAN providers protecting people with atrial ...

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its ... system and the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) devices were able to reduce ...

Boston Scientific Corp. reported positive data for two key ... Additionally, a sub-analysis of the OPTION trial demonstrated that the Watchman FLX device significantly reduced bleeding outcomes ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

The company states: “Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN FLX Left Atrial Appendage Closure Device ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific projected full-year revenue growth between 12.5% and 14.5%, compared with the prior year. The company's key growth drivers include its stroke prevention device, Watchman ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

One of the standout products in Boston Scientific's portfolio is the Watchman FLX Left Atrial Appendage Closure (LAAC) device. Recent clinical trial results from the OPTION study demonstrated the ...